Novo Nordisk A/S (NOVO-B.CO)

DKK 771.6

(0.22%)

Market Cap (In DKK)

3454.45 Billion

Revenue (In DKK)

232.26 Billion

Net Income (In DKK)

83.68 Billion

Avg. Volume

2.45 Million

Currency
DKK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
686.0-1033.2
PE
-
EPS
-
Beta Value
0.165
ISIN
DK0062498333
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lars Fruergaard Jorgensen
Employee Count
-
Website
https://www.novonordisk.com
Ipo Date
2001-01-06
Details
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.